[
    [
        {
            "time": "2019-08-27",
            "original_text": "恒瑞医药：公司及子公司药品获药监局临床试验通知书",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "药品",
                    "临床试验",
                    "通知书"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药：公司及子公司药品获药监局临床试验通知书",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-08-26",
            "original_text": "8月26日复盘:假阳线里要看到真东西 主力重点出击1股",
            "features": {
                "keywords": [
                    "复盘",
                    "假阳线",
                    "主力",
                    "出击"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "8月26日复盘:假阳线里要看到真东西 主力重点出击1股",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 2,
                "Entity_Density": 2,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-08-27",
            "original_text": "恒瑞医药(600276.SH)：注射用卡瑞利珠单抗(SHR-1210)获批临床试验",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "卡瑞利珠单抗",
                    "临床试验",
                    "获批"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药(600276.SH)：注射用卡瑞利珠单抗(SHR-1210)获批临床试验",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-08-27",
            "original_text": "龙津药业封涨停多只个股大涨 医药产业链板块有“抗跌”疗效？",
            "features": {
                "keywords": [
                    "龙津药业",
                    "涨停",
                    "医药产业链",
                    "抗跌"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "龙津药业封涨停多只个股大涨 医药产业链板块有“抗跌”疗效？",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-08-26",
            "original_text": "申万宏源一周晨会纪要合集（2019/8/26-2019/8/30）",
            "features": {
                "keywords": [
                    "申万宏源",
                    "晨会纪要",
                    "合集"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "申万宏源一周晨会纪要合集（2019/8/26-2019/8/30）",
                "Correlation": 2,
                "Sentiment": 5,
                "Importance": 3,
                "Impact": 2,
                "Duration": 3,
                "Entity_Density": 1,
                "Market_Scope": 6,
                "Time_Proximity": 4,
                "Headline_Structure": 4,
                "Source_Recency": 3
            }
        },
        {
            "time": "2019-08-26",
            "original_text": "【川财研究所*四季度展望】医药生物：板块迎来估值切换，关注四季度业绩优异个股",
            "features": {
                "keywords": [
                    "川财研究所",
                    "医药生物",
                    "估值切换",
                    "四季度",
                    "业绩"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【川财研究所*四季度展望】医药生物：板块迎来估值切换，关注四季度业绩优异个股",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-08-27",
            "original_text": "大额“花式”减持频现 今年以来上市公司高管减持逾5500次 减持股份数量",
            "features": {
                "keywords": [
                    "减持",
                    "上市公司",
                    "高管",
                    "5500次"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "大额“花式”减持频现 今年以来上市公司高管减持逾5500次 减持股份数量",
                "Correlation": 4,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-08-27",
            "original_text": "白马股何以批量创新高",
            "features": {
                "keywords": [
                    "白马股",
                    "创新高"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "白马股何以批量创新高",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        }
    ]
]